MCL

Maria Alice Willrich, Ph.D., explains kappa free light chain testing — Mayo Clinic Laboratories' data-driven approach to diagnose multiple sclerosis. The automated assay is more sensitive, cost-effective, and faster than traditional oligoclonal banding, enabling definitive answers for the challenging diagnosis.

Mayo Clinic researchers have developed and validated a new antibody test to diagnose multiple sclerosis (MS). The new test is an automated and cost-effective method compared to other tests used to diagnose MS, according to the research published in Mayo Clinic Proceedings. The test is now available through Mayo Clinic Laboratories.

Each day, some 40 to 45 thousand specimens are shipped to Mayo Clinic Laboratories in Rochester, Minnesota, from hospitals and other health care organizations around the world. And for every sample, there’s a patient to whom it belongs, someone on the other end hoping for answers to a challenging, perhaps even life-threatening, condition.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Venkatesh Bellamkonda, M.D., assistant professor of Emergency Medicine and the Wellness Officer for the Department of Emergency Medicine at Mayo Clinic, to discuss the importance of wellness and well-being.

John Lieske, M.D., discusses Mayo Clinic Laboratories' urinary ammonium testing. A test that takes the guesswork out of determining acid base disorders by giving nephrologists a true understanding of a patient’s true urinary ammonium level.

This Feature Includes: Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data.

Successful implementation of a new slide scanning and analysis platform across five laboratories represents a significant step forward in Mayo Clinic’s digital pathology program — an initiative that combines advanced technology with human expertise to better serve patients.

A Mayo Clinic Laboratories newborn screening panel detects a rare disease and paves the way for life-sustaining treatment.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Dr. Bill Morice, professor of Laboratory Medicine and Pathology, chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and president of Mayo Clinic Laboratories, to discuss the laboratory’s role in health and equity.

CPT Code updates posted to mayocliniclabs.com during the month of February

Audrey Schuetz, M.D., provides a detailed overview of Mayo Clinic Laboratories’ new culture-based extended spectrum beta lactamase (ESBL) testing. Used to screen for the presence of multi-drug resistant gram-negative bacteria in donor stool intended for fecal microbiota transplantation, the screening test is performed on stool or swab samples taken from around the anus to detect potentially harmful ESBL bacteria that could jeopardize the outcomes of fecal microbiota transplants -- especially in patients who carry the bacteria in their gut without getting sick.

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' stiff-person assay provides comprehensive evaluation for individuals on the spectrum of stiff-person syndrome. In addition to guiding treatment decisions, the assay can help confirm the most-severe stiff-person phenotype — known as PERM — which is associated with potential cancers.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Yasmeen Butt, M.D., Assistant Professor of Laboratory Medicine and Pathology, and Brittney Thiele, a medical student, both at Mayo Clinic’s Arizona campus, to discuss their Pathology Interest Group and the importance of having one.